Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Adaptimmune gets accelerated approval for Tecelra

October 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory trial.

Cobas Liat SARS-CoV-2, flu A/B, RSV test gets EUA

September 2024—Roche announced that the FDA has granted emergency use authorization for its Cobas Liat SARS-CoV-2, Influenza A/B, and RSV nucleic acid test for use on the Cobas Liat system. The automated multiplex real-time reverse transcription polymerase chain reaction test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus RNA in anterior nasal and nasopharyngeal swab specimens. Definitive results are generated in 20 minutes.

Siemens offers NT‑proBNPII assay on Atellica Solution

September 2024—Siemens Healthineers has added the NT‑proBNPII assay to its cardiac test menu on the Atellica Solution to help diagnose heart failure. The assay supports timely patient care with a first result available in 10 minutes. The company offers the NT-proBNPII and B-type natriuretic peptide tests on either the Atellica IM or Atellica CI analyzer.

Qiagen launches digital PCR assays for microbial applications

September 2024—Qiagen has launched 35 wet-lab tested digital PCR microbial DNA detection assays for its digital PCR platform QIAcuity. The assays are available on Qiagen’s research platform GeneGlobe and are designed to target a wide range of pathogens, including dengue virus serotypes one to four, mpox clades one and two, and chikungunya, as well as malaria and various sexually transmitted infections and urinary tract infections. The addition of these assays brings the company’s total microbial dPCR assay portfolio to more than 680 targets.

BD, Quest to develop companion diagnostics

September 2024—BD and Quest Diagnostics announced a worldwide collaboration agreement to develop, manufacture, and commercialize flow-cytometry–based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.

Sakura Finetek launches laser cassette printer

September 2024—Sakura Finetek Europe announced the launch of the Tissue-Tek xPrint LP laser cassette printer. Features of the laser printer include high-definition barcode printing at 2,500 dpi and a printing speed of up to 2.5 seconds per cassette. It is designed to print on Tissue-Tek Paraform cassettes of any color, without the need for calibration or additional setup. Print quality is robust and resistant to heat, alcohol, xylene, acid, and scratching, as well as other common laboratory conditions. The printer supports a wide range of content, including logos, barcodes, QR codes, data matrices, and text that can be displayed in the Windows system.

FDA approves Illumina cancer biomarker test plus two CDxs

September 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.

Enzyme calibration verifiers for creatine kinase testing

September 2024—Verichem Laboratories now offers multilevel calibration verification materials for creatine kinase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The calibration verifiers are intended to be treated as patient specimens and are available for use on a variety of wet clinical chemistry systems, including from Beckman Coulter, Abbott, Siemens Healthineers, and Roche. The kit contains 5 mL of material for each of the six levels and is stable for 18 months from the manufacturing date.

Thermo Fisher, NCI partner on myeloMATCH umbrella trial

September 2024—Thermo Fisher Scientific is partnering with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial to help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome. The study involves testing patients’ bone marrow and blood for certain genetic biomarkers using Thermo Fisher’s next-generation sequencing technology so clinical sites can more quickly match patients with an appropriate clinical trial that tests a treatment designed to target specific mutations present in the samples.

MARKETPLACE

TRENDING